CostPlus and implications for generic imatinib
Lancet Reg Health Am
.
2022 Jul 8:13:100317.
doi: 10.1016/j.lana.2022.100317.
eCollection 2022 Sep.
Authors
Kristina Jenei
1
,
Mark P Lythgoe
2
,
Vinay Prasad
3
Affiliations
1
School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
2
Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
3
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, United States.
PMID:
36777318
PMCID:
PMC9903877
DOI:
10.1016/j.lana.2022.100317
No abstract available